Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
cannabis investing Cannara Insiders Form Buying Group to Fully Acquire FSD/FV Pharma’s Position in Cannara
cannabis investing FSD Pharma Generates $7.7 Million in Proceeds and 670 Percent Return on Investment through Sale of Interest in Cannara Biotech
cannabis investing Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce
cannabis investing Cannara Biotech Submits Site Evidence Package to Health Canada for its Quebec Facility
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
